Ardelyx (ARDX) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue reached $73.2M, up from $22.3M in Q2 2023, driven by strong performances from IBSRELA and XPHOZAH, with net product sales of $35.4M and $37.1M, respectively.

• Net loss for Q2 2024 was $16.5M (or $0.07/share), a slight improvement from $17.1M (or $0.08/share) in Q2 2023.

• Ended Q2 with $186M in cash, cash equivalents, and short-term investments, supporting ongoing commercialization and R&D.

• Operating expenses and SG&A nearly doubled year-over-year due to commercialization efforts for IBSRELA and XPHOZAH.

• Company is actively advocating and pursuing legal action to prevent XPHOZAH from being included in the Medicare bundle.

Financial highlights

• Q2 2024 total revenue: $73.2M, up 228% from $22.3M in Q2 2023; six-month revenues were $119.2M, up 254% year-over-year.

• IBSRELA net product sales: $35.4M, up from $18.3M in Q2 2023 and 25% higher than Q1 2024.

• XPHOZAH net product sales: $37.1M, up from $15.2M in Q1 2024.

• Cost of goods sold for Q2 2024 was $9.4M, up 170% year-over-year.

• Net loss per share was $(0.07) for Q2 2024, compared to $(0.08) in Q2 2023.

Outlook and guidance

• Reiterates full-year 2024 IBSRELA U.S. net product sales guidance of $140M–$150M.

• Expects continued strong quarter-over-quarter growth for IBSRELA in the second half of 2024.

• Management expects continued operating losses as commercialization expands.

• Cash on hand is expected to fund operations for at least one year from the financial statement issuance.

• Future revenue growth depends on market acceptance, reimbursement, and regulatory outcomes for XPHOZAH.